ガリキシマブ
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2014/12/01 20:07:32」(JST)
[Wiki en表示]
Galiximab ?
Monoclonal antibody |
Type |
Whole antibody |
Source |
Chimeric (primate/human) |
Target |
CD80 |
Clinical data |
Legal status |
?
|
Identifiers |
CAS number |
357613-77-5 N |
ATC code |
None |
UNII |
S9OX9692ZB Y |
KEGG |
D04295 Y |
Chemical data |
Formula |
? |
N (what is this?) (verify) |
Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009[update], it is undergoing Phase III clinical trials.[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[2]
References
- ^ Biogen Idec: Pipeline
- ^ WHO Drug Information
External links
Immunomodulators: Immunosuppressive drugs / Immunosuppressants (L04)
|
|
Intracellular
(initiation) |
Antimetabolites
|
- purine synthesis inhibitors: Azathioprine
- Mycophenolic acid
- pyrimidine synthesis inhibitors: Leflunomide
- Teriflunomide
antifolate: Methotrexate
|
|
Macrolides/
other IL-2 inhibitors
|
- FKBP/Cyclophilin/Calcineurin: Tacrolimus
- Ciclosporin
- Pimecrolimus
|
|
IMiDs
|
- Lenalidomide
- Pomalidomide
- Thalidomide
|
|
|
Intracellular
(reception) |
IL-1 receptor antagonists
|
|
|
mTOR
|
- Sirolimus
- Everolimus
- Ridaforolimus
- Temsirolimus
- Umirolimus
- Zotarolimus
|
|
|
Extracellular |
Antibodies
|
Monoclonal
|
Serum target
(noncellular)
|
- Complement component 5 (Eculizumab)
- TNF (Adalimumab
- Afelimomab
- Certolizumab pegol
- Golimumab
- Infliximab
- Nerelimomab)
- Interleukin 5 (Mepolizumab)
- Immunoglobulin E (Omalizumab)
- IL-12 and IL-23 (Lebrikizumab
- Ustekinumab)
|
|
Cellular target
|
- CD3 (Muromonab-CD3
- Otelixizumab
- Teplizumab
- Visilizumab)
- CD4 (Clenoliximab
- Keliximab
- Zanolimumab)
- CD11a (Efalizumab)
- CD18 (Erlizumab)
- CD20 (Obinutuzumab
- Rituximab
- Ocrelizumab
- Pascolizumab)
- CD23 (Gomiliximab
- Lumiliximab)
- CD40 (Teneliximab
- Toralizumab)
- CD62L/L-selectin (Aselizumab)
- CD80 (Galiximab)
- CD147/Basigin (Gavilimomab)
- CD154 (Ruplizumab)
- BLyS (Belimumab
- Blisibimod)
- CTLA-4 (Ipilimumab
- Tremelimumab)
- CAT (Bertilimumab
- Lerdelimumab
- Metelimumab)
- Integrin (Natalizumab)
- Interleukin-6 receptor (Tocilizumab)
- LFA-1 (Odulimomab)
- IL-2 receptor/CD25 (Basiliximab
- Daclizumab
- Inolimomab)
- T-lymphocyte (Zolimomab aritox)
|
|
Unsorted
|
- Atorolimumab
- Cedelizumab
- Fontolizumab
- Maslimomab
- Morolimumab
- Pexelizumab
- Reslizumab
- Rovelizumab
- Siplizumab
- Talizumab
- Telimomab aritox
- Vapaliximab
- Vepalimomab
|
|
|
Polyclonal
|
- Anti-thymocyte globulin
- Anti-lymphocyte globulin
|
|
|
-cept (Fusion)
|
- CTLA-4 (Abatacept
- Belatacept)
- TNF inhibitor (Etanercept
- Pegsunercept)
- Aflibercept
- Alefacept
- Rilonacept
|
|
|
|
cell/phys/auag/auab/comp, igrc
|
|
|
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.
- Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC, Cheson BD.SourceDepartment of Medicine, Lymphoma/Myeloma Section, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. Myron.czuczman@roswellpark.org
- Annals of oncology : official journal of the European Society for Medical Oncology / ESMO.Ann Oncol.2012 Sep;23(9):2356-62. doi: 10.1093/annonc/mdr620. Epub 2012 Feb 22.
- BACKGROUND: This phase II CALGB trial evaluated the activity and safety of an extended induction schedule of galiximab (G) plus rituximab (R) in untreated follicular lymphoma (FL). PatieNTS AND METHODS: Patients with previously untreated FL (grades 1, 2, 3a) received 4 weekly infusions of G + R, fol
- PMID 22357442
- CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma.
- Dakappagari N, Ho SN, Gascoyne RD, Ranuio J, Weng AP, Tangri S.SourceGlobal Clinical Assay Group, Pfizer, Inc, San Diego, California 92121, USA.
- Cytometry. Part B, Clinical cytometry.Cytometry B Clin Cytom.2012 Mar;82(2):112-9. doi: 10.1002/cyto.b.20631. Epub 2011 Nov 10.
- BACKGROUND: CD80 is a member of the B7 family of immune coregulatory proteins that mediate both immune activation and suppression. CD80 in particular has recently been shown to play an important role in supporting immune suppression through interactions with B7-H1. CD80 has been identified as a ther
- PMID 22076940
Related Links
- ... (アレムツズマブCampath)、の他に、本稿で述べる抗CD80抗体 (ガリキシマブgaliximab)や抗CD2 抗体(シプリズマブMEDI-507 [siplizumab])、抗CD30抗体 (SGN-30 and MDX-060 [iratumumab]), さらにCD40抗体 (SGN-40)など 、が ...
- Definition of galiximab in the Definitions.net dictionary. Meaning of galiximab. What does galiximab mean? Information and translations of galiximab in the most comprehensive dictionary definitions resource on the web.
Related Pictures
★リンクテーブル★
[★]
- 関
- モノクローナル抗体
mab